Experimental and clinical data have demonstrated that activating the immune system in the CNS can be destructive. However, other studies have shown that enhancing an immune response can be therapeutic, and several clinical trials have been initiated with the aim of boosting immune responses in the CNS of individuals with spinal cord injury, multiple sclerosis and Alzheimer's disease. Here, we evaluate the controversies in the field and discuss the remaining scientific challenges that are associated with enhancing immune function in the CNS to treat neurological diseases.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Chondroitin sulfate proteoglycans prevent immune cell phenotypic conversion and inflammation resolution via TLR4 in rodent models of spinal cord injury
Nature Communications Open Access 25 May 2022
Synaptic or Non-synaptic? Different Intercellular Interactions with Retinal Ganglion Cells in Optic Nerve Regeneration
Molecular Neurobiology Open Access 09 March 2022
Journal of Neuroinflammation Open Access 21 August 2020
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Galea, I., Bechmann, I. & Perry, V. H. What is immune privilege (not)? Trends Immunol. 28, 12–18 (2007).
Feuerstein, G. Z., Wang, X. & Barone, F. C. The role of cytokines in the neuropathology of stroke and neurotrauma. Neuroimmunomodulation. 5, 143–159 (1998).
Barnett, M. H., Henderson, A. P. & Prineas, J. W. The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Mult. Scler. 12, 121–132 (2006).
Schroeter, M. & Jander, S. T-cell cytokines in injury-induced neural damage and repair. Neuromolecular. Med. 7, 183–195 (2005).
Schwartz, M. Harnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disorders. Cell Mol. Neurobiol. 21, 617–627 (2001).
Schwartz, M. & Kipnis, J. Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries. Trends Mol. Med. 7, 252–258 (2001).
Hauwel, M. et al. Innate (inherent) control of brain infection, brain inflammation and brain repair: the role of microglia, astrocytes, “protective” glial stem cells and stromal ependymal cells. Brain Res. Brain Res. Rev. 48, 220–233 (2005).
Farina, C., Aloisi, F. & MeinL, E. Astrocytes are active players in cerebral innate immunity. Trends Immunol. 28, 138–145 (2007).
Kreutzberg, G. W. Microglia: A sensor for pathological events in the CNS. Trends Neurosci. 19, 312–318 (1996).
Nathan, C. Points of control in inflammation. Nature 420, 846–852 (2002).
Matzinger, P. The danger model: a renewed sense of self. Science 296, 301–305 (2002).
Matzinger, P. Friendly and dangerous signals: is the tissue in control? Nature Immunol. 8, 11–13 (2007).
Davalos, D. et al. ATP mediates rapid microglial response to local brain injury in vivo. Nature Neurosci. 8, 752–758 (2005).
Cotrina, M. L., Lin, J. H., Lopez-Garcia, J. C., Naus, C. C. & Nedergaard, M. ATP-mediated glia signaling. J. Neurosci. 20, 2835–2844 (2000).
Koizumi, S. et al. UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 446, 1091–1095 (2007).
Ohsawa, K. et al. Involvement of P2X4 and P2Y12 receptors in ATP-induced microglial chemotaxis. Glia. 55, 604–616 (2007).
Dong, Y. & Benveniste, E. N. Immune function of astrocytes. Glia. 36, 180–190 (2001).
Elkabes, S., DiCicco-Bloom, E. M. & Black, I. B. Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function. J. Neurosci. 16, 2508–2521 (1996).
Persson, M., Brantefjord, M., Hansson, E. & Ronnback, L. Lipopolysaccharide increases microglial GLT-1 expression and glutamate uptake capacity in vitro by a mechanism dependent on TNF-α. Glia. 51, 111–120 (2005).
Bessis, A., Bechade, C., Bernard, D. & Roumier, A. Microglial control of neuronal death and synaptic properties. Glia 55, 233–238 (2007).
Pender, M. P. & Rist, M. J. Apoptosis of inflammatory cells in immune control of the nervous system: role of glia. Glia 36, 137–144 (2001).
Faulkner, J. R. et al. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J. Neurosci. 24, 2143–2155 (2004).
Myer, D. J., Gurkoff, G. G., Lee, S. M., Hovda, D. A. & Sofroniew, M. V. Essential protective roles of reactive astrocytes in traumatic brain injury. Brain 129, 2761–2772 (2006).
Bush, T. G. et al. Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 23, 297–308 (1999).
Okada, S. et al. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nature Med. 12, 829–834 (2006).
Brambilla, R. et al. Inhibition of astroglial nuclear factor κB reduces inflammation and improves functional recovery after spinal cord injury. J. Exp. Med. 202, 145–156 (2005).
Simard, A. R., Soulet, D., Gowing, G., Julien, J. P. & Rivest, S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49, 489–502 (2006).
Lalancette-Hebert, M., Gowing, G., Simard, A., Weng, Y. C. & Kriz, J. Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J. Neurosci. 27, 2596–2605 (2007).
Neumann, H. Control of glial immune function by neurons. Glia 36, 191–199 (2001).
Griffiths, M., Neal, J. W. & Gasque, P. Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins. Int. Rev. Neurobiol. 82, 29–55 (2007).
Cardona, A. E. et al. Control of microglial neurotoxicity by the fractalkine receptor. Nature Neurosci. 9, 917–924 (2006).
Hoek, R. M. et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290, 1768–1771 (2000).
Mott, R. T. et al. Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production. Glia 46, 369–379 (2004).
Bechmann, I. et al. Reactive astrocytes upregulate Fas (CD95) and Fas ligand (CD95L) expression but do not undergo programmed cell death during the course of anterograde degeneration. Glia 32, 25–41 (2000).
Dirnagl, U., Iadecola, C. & Moskowitz, M. A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22, 391–397 (1999).
Kuhlmann, T., Bitsch, A., Stadelmann, C., Siebert, H. & Bruck, W. Macrophages are eliminated from the injured peripheral nerve via local apoptosis and circulation to regional lymph nodes and the spleen. J. Neurosci. 21, 3401–3408 (2001).
Mutlu, L. et al. Tolerogenic effect of fiber tract injury: reduced EAE severity following entorhinal cortex lesion. Exp. Brain Res. 178, 542–553 (2007).
Savill, J., Dransfield, I., Gregory, C. & Haslett, C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nature Rev. Immunol. 2, 965–975 (2002).
Velardo, M. J. et al. Patterns of gene expression reveal a temporally orchestrated wound healing response in the injured spinal cord. J. Neurosci. 24, 8562–8576 (2004).
Goodman, J. H., Bingham, W. G., Jr. & Hunt, W. E. Platelet aggregation in experimental spinal cord injury. Ultrastructural observations. Arch Neurol 36, 197–201 (1979).
Koyanagi, I., Iwasaki, Y., Isu, T., Akino, M. & Abe, H. Significance of spinal cord swelling in the prognosis of acute cervical spinal cord injury. Paraplegia 27, 190–197 (1989).
Aarabi, B. et al. Outcome following decompressive craniectomy for malignant swelling due to severe head injury. J. Neurosurg. 104, 469–479 (2006).
Nagy, Z., Kolev, K., Csonka, E., Vastag, M. & Machovich, R. Perturbation of the integrity of the blood-brain barrier by fibrinolytic enzymes. Blood Coagul. Fibrinolysis 9, 471–478 (1998).
Armao, D., Kornfeld, M., Estrada, E. Y., Grossetete, M. & Rosenberg, G. A. Neutral proteases and disruption of the blood-brain barrier in rat. Brain Res. 767, 259–264 (1997).
Weber, C., Fraemohs, L. & Dejana, E. The role of junctional adhesion molecules in vascular inflammation. Nature Rev. Immunol. 7, 467–477 (2007).
Engelhardt, B. & Ransohoff, R. M. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 26, 485–495 (2005).
Gingrich, M. B., Junge, C. E., Lyuboslavsky, P. & Traynelis, S. F. Potentiation of NMDA receptor function by the serine protease thrombin. J. Neurosci. 20, 4582–4595 (2000).
Suo, Z. et al. Participation of protease-activated receptor-1 in thrombin-induced microglial activation. J. Neurochem. 80, 655–666 (2002).
Ohnishi, M. et al. Involvement of thrombin and mitogen-activated protein kinase pathways in hemorrhagic brain injury. Exp. Neurol. 206, 43–52 (2007).
Choi, S. H., Joe, E. H., Kim, S. U. & Jin, B. K. Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo. J. Neurosci. 23, 5877–5886 (2003).
Kadota, E. et al. Biological functions of extravasated serum IgG in rat brain. Acta Neurochir. Suppl 76, 69–72 (2000).
Ankeny, D. P., Lucin, K. M., Sanders, V. M., McGaughy, V. M. & Popovich, P. G. Spinal cord injury triggers systemic autoimmunity: evidence for chronic B lymphocyte activation and lupus-like autoantibody synthesis. J. Neurochem. 99, 1073–1087 (2006).
Anderson, A. J., Robert, S., Huang, W., Young, W. & Cotman, C. W. Activation of complement pathways after contusion-induced spinal cord injury. J. Neurotrauma 21, 1831–1846 (2004).
Leinhase, I. et al. Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation. BMC Neurosci. 7, 55 (2006).
Stahel, P. F., Morganti-Kossman, M. C. & Kossman, T. The role of the complement system in traumatic brain injury. Brain Res. Rev. 27, 243–256 (1998).
Stahel, P. F. et al. Intrathecal levels of complement-derived soluble membrane attack complex (sC5b-9) correlate with blood-brain barrier dysfunction in patients with traumatic brain injury. J. Neurotrauma 18, 773–781 (2001).
Martin, P. & Leibovich, S. J. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol. 15, 599–607 (2005).
Martin, P. Wound healing — aiming for perfect skin regeneration. Science 276, 75–81 (1997).
Hashimoto, Y. et al. Transforming growth factor β2 autocrinally mediates neuronal cell death induced by amyloid-β. J. Neurosci. Res. 83, 1039–1047 (2006).
Floden, A. M., Li, S. & Combs, C. K. β-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor α and NMDA receptors. J. Neurosci. 25, 2566–2575 (2005).
Hailer, N. P., Vogt, C., Korf, H. W. & Dehghani, F. Interleukin-1β exacerbates and interleukin-1 receptor antagonist attenuates neuronal injury and microglial activation after excitotoxic damage in organotypic hippocampal slice cultures. Eur. J. Neurosci. 21, 2347–2360 (2005).
Silver, J. & Miller, J. H. Regeneration beyond the glial scar. Nature Rev. Neurosci. 5, 146–156 (2004).
Sofroniew, M. V. Reactive astrocytes in neural repair and protection. Neuroscientist. 11, 400–407 (2005).
Wang, Y., Moges, H., Bharucha, Y. & Symes, A. Smad3 null mice display more rapid wound closure and reduced scar formation after a stab wound to the cerebral cortex. Exp. Neurol. 203, 168–184 (2007).
Smith, G. M. & Strunz, C. Growth factor and cytokine regulation of chondroitin sulfate proteoglycans by astrocytes. Glia 52, 209–218 (2005).
Colavita, A., Krishna, S., Zheng, H., Padgett, R. W. & Culotti, J. G. Pioneer axon guidance by UNC-129, a C. elegans TGF-β. Science 281, 706–709 (1998).
Miao, T. et al. Suppressor of cytokine signaling-3 suppresses the ability of activated signal transducer and activator of transcription-3 to stimulate neurite growth in rat primary sensory neurons. J. Neurosci. 26, 9512–9519 (2006).
Kubo, M., Hanada, T. & Yoshimura, A. Suppressors of cytokine signaling and immunity. Nature Immunol. 4, 1169–1176 (2003).
Wang, J. & Campbell, I. L. Cytokine signaling in the brain: putting a SOCS in it? J. Neurosci. Res. 67, 423–427 (2002).
Martin, P. et al. Wound healing in the PU.1 null mouse — tissue repair is not dependent on inflammatory cells. Curr. Biol. 13, 1122–1128 (2003).
Ashcroft, G. S. et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nature Cell Biol. 1, 260–266 (1999).
Dang, C., Ting, K., Soo, C., Longaker, M. T. & Lorenz, H. P. Fetal wound healing current perspectives. Clin. Plast. Surg. 30, 13–23 (2003).
Triarhou, L. C. & Herndon, R. M. Effect of macrophage inactivation on the neuropathology of lysolecithin-induced demyelination. Br. J. Exp. Pathol. 66, 293–301 (1985).
Felts, P. A. et al. Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide. Brain 128, 1649–1666 (2005).
Schonberg, D. L., Popovich, P. G. & McTigue, D. M. Oligodendrocyte generation is differentially influenced by Toll-like receptor (TLR) 2 and TLR4-mediated intraspinal macrophage activation. J. Neuropathol. Exp. Neurol. 66, 1124–1135 (2007).
Bieber, A. J., Kerr, S. & Rodriguez, M. Efficient central nervous system remyelination requires T cells. Ann. Neurol. 53, 680–684 (2003).
Yin, Y. et al. Macrophage-derived factors stimulate optic nerve regeneration. J. Neurosci. 23, 2284–2293 (2003).
Yin, Y. et al. Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. Nature Neurosci. 9, 843–852 (2006).
Fitch, M. T. & Silver, J. Activated macrophages and the blood-brain barrier: inflammation after CNS injury leads to increases in putative inhibitory molecules. Exp. Neurol. 148, 587–603 (1997).
Popovich, P. G. et al. The neuropathological and behavioral consequences of intraspinal microglial/macrophage activation. J. Neuropathol. Exp. Neurol. 61, 623–633 (2002).
Kotter, M. R., Setzu, A., Sim, F. J., van Rooijen, N. & Franklin, R. J. Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia 35, 204–212 (2001).
Ghasemlou, N., Jeong, S. Y., Lacroix, S. & David, S. T cells contribute to lysophosphatidylcholine-induced macrophage activation and demyelination in the CNS. Glia 55, 294–302 (2007).
Taub, R. Liver regeneration: from myth to mechanism. Nature Rev. Mol. Cell Biol. 5, 836–847 (2004).
Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 (2002).
Vallieres, N., Berard, J. L., David, S. & Lacroix, S. Systemic injections of lipopolysaccharide accelerates myelin phagocytosis during Wallerian degeneration in the injured mouse spinal cord. Glia 53, 103–113 (2006).
Rotshenker, S. Microglia and macrophage activation and the regulation of complement-receptor-3 (CR3/MAC-1)-mediated myelin phagocytosis in injury and disease. J. Mol. Neurosci. 21, 65–72 (2003).
Hashimoto, M. et al. Involvement of glial cell line-derived neurotrophic factor in activation processes of rodent macrophages. J. Neurosci. Res. 79, 476–487 (2005).
Li, W. W., Setzu, A., Zhao, C. & Franklin, R. J. Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination. J. Neuroimmunol. 158, 58–66 (2005).
Leon, S., Yin, Y., Nguyen, J., Irwin, N. & Benowitz, L. I. Lens injury stimulates axon regeneration in the mature rat optic nerve. J Neurosci 20, 4615–4626 (2000).
Lazarov-Spiegler, O., Solomon, A. S. & Schwartz, M. Peripheral nerve-stimulated macrophages simulate a peripheral nerve-like regenerative response in rat transected optic nerve. Glia 24, 329–337 (1998).
Bouhy, D. et al. Delayed GM-CSF treatment stimulates axonal regeneration and functional recovery in paraplegic rats via an increased BDNF expression by endogenous macrophages. FASEB J. 20, 1239–1241 (2006).
Mitrasinovic, O. M. & Murphy, G. M. Jr. Accelerated phagocytosis of amyloid-β by mouse and human microglia overexpressing the macrophage colony-stimulating factor receptor. J. Biol. Chem. 277, 29889–29896 (2002).
Shie, F. S., Breyer, R. M. & Montine, T. J. Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Aβ phagocytosis yet lack Aβ-activated neurotoxicity. Am. J. Pathol. 166, 1163–1172 (2005).
Lazarov-Spiegler, O. et al. Transplantation of activated macrophages overcomes central nervous system regrowth failure. FASEB J. 10, 1296–1302 (1996).
Rapalino, O. et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nature Med. 4, 814–821 (1998).
Butovsky, O. et al. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc. Natl Acad. Sci. USA 103, 11784–11789 (2006).
Perry, V. H., Brown, M. C. & Gordon, S. The macrophage response to central and peripheral nerve injury. A possible role for macrophages in regeneration. J. Exp. Med. 165, 1218–1223 (1987).
Zeev-Brann, A. B., Lazarov-Spiegler, O., Brenner, T. & Schwartz, M. Differential effects of central and peripheral nerves on macrophages and microglia. Glia 23, 181–190 (1998).
Knoller, N. et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J. Neurosurg. Spine 3, 173–181 (2005).
Chang, H. T. Subacute human spinal cord contusion: few lymphocytes and many macrophages. Spinal Cord. 45, 174–182 (2007).
Fleming, J. C. et al. The cellular inflammatory response in human spinal cords after injury. Brain 129, 3249–3269 (2006).
Dusart, I. & Schwab, M. E. Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur. J. Neurosci. 6, 712–724 (1994).
Popovich, P. G., Wei, P. & Stokes, B. T. The cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J. Comp. Neurol. 377, 443–464 (1997).
Kigerl, K. A., McGaughy, V. M. & Popovich, P. G. Comparative analysis of lesion development and intraspinal inflammation in four strains of mice following spinal contusion injury. J. Comp. Neurol. 494, 578–594 (2006).
Stout, R. D. et al. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J. Immunol. 175, 342–349 (2005).
Schnell, L., Fearn, S., Schwab, M., Perry, V. H. & Anthony, D. C. Cytokine-induced acute inflammation in the brain and spinal cord. J. Neuropathol. Exp. Neurol. 58, 245–254 (1999).
Schnell, L., Fearn, S., Klassen, H., Schwab, M. E. & Perry, V. H. Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord. Eur. J. Neurosci. 11, 3648–3658 (1999).
Streit, W. J. et al. Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp. Neurol. 152, 74–87 (1998).
Pan, J. Z. et al. Cytokine activity contributes to induction of inflammatory cytokine mRNAs in spinal cord following contusion. J. Neurosci. Res. 68, 315–322 (2002).
Pineau, I. & Lacroix, S. Proinflammatory cytokine synthesis in the injured mouse spinal cord: multiphasic expression pattern and identification of the cell types involved. J. Comp. Neurol. 500, 267–285 (2007).
Makwana, M. et al. Endogenous transforming growth factor β 1 suppresses inflammation and promotes survival in adult CNS. J. Neurosci. 27, 11201–11213 (2007).
Liu, Y. et al. Suppression of microglial inflammatory activity by myelin phagocytosis: role of p47-PHOX-mediated generation of reactive oxygen species. J. Neurosci. 26, 12904–12913 (2006).
Giulian, D. & Robertson, C. Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord. Ann. Neurol. 27, 33–42 (1990).
Blight, A. R. Effects of silica on the outcome from experimental spinal cord injury: implication of macrophages in secondary tissue damage. Neuroscience 60, 263–273 (1994).
Popovich, P. G. et al. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. Exp. Neurol. 158, 351–365 (1999).
Gris, D. et al. Transient blockade of the CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function. J. Neurosci. 24, 4043–4051 (2004).
Yong, V. W. et al. The promise of minocycline in neurology. Lancet Neurol. 3, 744–751 (2004).
Lampl, Y. et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 69, 1404–1410 (2007).
Gordon, P. H. et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 6, 1045–1053 (2007).
Nahrendorf, M. et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 204, 3037–3047 (2007).
Zhu, B. et al. CD11b+Ly-6Chigh suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 179, 5228–5237 (2007).
Weber, M. S. et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nature Med. 13, 935–943 (2007).
Hauben, E. & Schwartz, M. Therapeutic vaccination for spinal cord injury: helping the body to cure itself. Trends Pharmacol. Sci. 24, 7–12 (2003).
Hafler, D. A. Multiple sclerosis. J. Clin. Invest 113, 788–794 (2004).
Prat, A. & Antel, J. Pathogenesis of multiple sclerosis. Curr. Opin. Neurol. 18, 225–230 (2005).
Potas, J. R. et al. Augmented locomotor recovery after spinal cord injury in the athymic nude rat. J. Neurotrauma 23, 660–673 (2006).
Fee, D. et al. Activated/effector CD4+ T cells exacerbate acute damage in the central nervous system following traumatic injury. J. Neuroimmunol. 136, 54–66 (2003).
Yilmaz, G., Arumugam, T. V., Stokes, K. Y. & Granger, D. N. Role of T lymphocytes and interferon-γ in ischemic stroke. Circulation 113, 2105–2112 (2006).
Moalem, G., Xu, K. & Yu, L. T lymphocytes play a role in neuropathic pain following peripheral nerve injury in rats. Neuroscience 129, 767–777 (2004).
Ankeny, D. P. & Popovich, P. G. Central nervous system and non-central nervous system antigen vaccines exacerbate neuropathology caused by nerve injury. Eur. J. Neurosci. 25, 2053–2064 (2007).
Zipp, F., Krammer, P. H. & Weller, M. Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system. Immunol Today 20, 550–554 (1999).
Aktas, O., Schulze-Topphoff, U. & Zipp, F. The role of TRAIL/TRAIL receptors in central nervous system pathology. Front Biosci. 12, 2912–2921 (2007).
Aktas, O. et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46, 421–432 (2005).
Giuliani, F., Goodyer, C. G., Antel, J. P. & Yong, V. W. Vulnerability of human neurons to T cell-mediated cytotoxicity. J. Immunol. 171, 368–379 (2003).
Nitsch, R. et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356, 827–828 (2000).
Neumann, H., Medana, I. M., Bauer, J. & Lassmann, H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 25, 313–319 (2002).
Giraudon, P. et al. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J. Immunol. 172, 1246–1255 (2004).
Shaked, I. et al. Protective autoimmunity: interferon-γ enables microglia to remove glutamate without evoking inflammatory mediators. J. Neurochem. 92, 997–1009 (2005).
Moalem, G. et al. Autoimmune T-cells protect neurons from secondary degeneration after central nervous system axotomy. Nature Med. 5, 49–55 (1999).
Moalem, G. et al. Production of neurotrophins by activated T-cells: implications for neuroprotective autoimmunity. J. Autoimmun. 15, 331–345 (2000).
Barouch, R. & Schwartz, M. Autoreactive T cells induce neurotrophin production by immune and neural cells in injured rat optic nerve: implications for protective autoimmunity. FASEB J. 16, 1304–1306 (2002).
Butovsky, O. et al. Microglia activated by IL-4 or IFN-γ differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol. Cell Neurosci. 31, 149–160 (2006).
Ziv, Y., Avidan, H., Pluchino, S., Martino, G. & Schwartz, M. Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury. Proc. Natl Acad. Sci. USA 103, 13174–13179 (2006).
Ben Hur, T. Immunomodulation by neural stem cells. J. Neurol. Sci. 265, 102–104 (2008).
Imitola, J. et al. Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli. Am. J. Pathol. 164, 1615–1625 (2004).
Einstein, O. et al. Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression. Ann. Neurol. 61, 209–218 (2007).
Uccelli, A., Pistoia, V. & Moretta, L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol. 28, 219–226 (2007).
Pluchino, S. et al. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 436, 266–271 (2005).
Ben Hur, T. et al. Effects of proinflammatory cytokines on the growth, fate, and motility of multipotential neural precursor cells. Mol. Cell Neurosci. 24, 623–631 (2003).
Andrews, T., Zhang, P. & Bhat, N. R. TNFα potentiates IFNγ-induced cell death in oligodendrocyte progenitors. J. Neurosci. Res. 54, 574–583 (1998).
Monje, M. L., Toda, H. & Palmer, T. D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 302, 1760–1765 (2003).
Kim, J. B. et al. Dexamethasone inhibits proliferation of adult hippocampal neurogenesis in vivo and in vitro. Brain Res. 1027, 1–10 (2004).
Battista, D., Ferrari, C. C., Gage, F. H. & Pitossi, F. J. Neurogenic niche modulation by activated microglia: transforming growth factor β increases neurogenesis in the adult dentate gyrus. Eur. J. Neurosci. 23, 83–93 (2006).
Huang, D. W., McKerracher, L., Braun, P. E. & David, S. A therapeutic vaccine approach to stimulate axon regeneration in the adult mammalian spinal cord. Neuron 24, 639–647 (1999).
Kaku, M. et al. Amyloid β protein deposition and neuron loss in osteopetrotic (op/op) mice. Brain Res. Brain Res. Protoc. 12, 104–108 (2003).
Fiala, M. et al. Ineffective phagocytosis of amyloid-β by macrophages of Alzheimer's disease patients. J. Alzheimers. Dis. 7, 221–232 (2005).
Xu, G. et al. Recombinant DNA vaccine encoding multiple domains related to inhibition of neurite outgrowth: a potential strategy for axonal regeneration. J. Neurochem. 91, 1018–1023 (2004).
Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177 (1999).
Lemere, C. A. et al. Alzheimer's disease aβ vaccine reduces central nervous system aβ levels in a non-human primate, the Caribbean vervet. Am. J. Pathol. 165, 283–297 (2004).
Sicotte, M. et al. Immunization with myelin or recombinant Nogo-66/MAG in alum promotes axon regeneration and sprouting after corticospinal tract lesions in the spinal cord. Mol. Cell Neurosci. 23, 251–263 (2003).
Heeger, P. S. et al. Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant. J. Immunol. 164, 5771–5781 (2000).
Falcone, M. & Bloom, B. R. A T-helper cell 2 (Th2) immune response against non-self antigens modifies the cytokine profile of autoimmune T-cells and protects against experimental allergic encephalomyelitis. J. Exp. Med. 185, 901–907 (1997).
Karnezis, T. et al. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nature Neurosci. 7, 736–744 (2004).
Hauben, E. et al. Vaccination with a Nogo-A-derived peptide after incomplete spinal-cord injury promotes recovery via a T-cell-mediated neuroprotective response: comparison with other myelin antigens. Proc. Natl Acad. Sci. USA 98, 15173–15178 (2001).
Becker, K. J. et al. Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia. Proc. Natl Acad. Sci. USA 94, 10873–10878 (1997).
Frenkel, D. et al. Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells. J. Immunol. 171, 6549–6555 (2003).
Khoury, S. J., Hancock, W. W. & Weiner, H. L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176, 1355–1364 (1992).
Gee, J. M., Kalil, A., Thullbery, M. & Becker, K. J. Induction of Immunologic Tolerance to Myelin Basic Protein Prevents Central Nervous System Autoimmunity and Improves Outcome After Stroke. Stroke (2008).
Whitacre, C. C., Gienapp, Orosz, C. G. & Bitar, D. M. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J. Immunol. 147, 2155–2163 (1991).
Benson, J. M. et al. Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis. J. Immunol. 162, 6247–6254 (1999).
Popovich, P. G., Yu, J. Y. & Whitacre, C. C. Spinal cord neuropathology in rat experimental autoimmune encephalomyelitis: modulation by oral administration of myelin basic protein. J. Neuropathol. Exp. Neurol. 56, 1323–1338 (1997).
Weiner, H. L. et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259, 1321–1324 (1993).
Wiendl, H. & Hohlfeld, R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16, 183–200 (2002).
Bar-Or, A. et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch. Neurol. 64, 1407–1415 (2007).
Nicoll, J. A. et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nature Med. 9, 448–452 (2003).
Gilman, S. et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553–1562 (2005).
Orgogozo, J. M. et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61, 46–54 (2003).
Fox, N. C. et al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64, 1563–1572 (2005).
Ferrer, I., Boada, R. M., Sanchez Guerra, M. L., Rey, M. J. & Costa-Jussa, F. Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease. Brain Pathol. 14, 11–20 (2004).
Nicoll, J. A. et al. Aβ species removal after aβ42 immunization. J. Neuropathol. Exp. Neurol. 65, 1040–1048 (2006).
Masliah, E. et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129–131 (2005).
Hock, C. et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547–554 (2003).
Lichtlen, P. & Mohajeri, M. H. Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J. Neurochem. (2007).
Gardberg, A. S. et al. Molecular basis for passive immunotherapy of Alzheimer's disease. Proc. Natl Acad. Sci. USA 104, 15659–15664 (2007).
Prada, C. M. et al. Antibody-mediated clearance of amyloid-β peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging. J. Neurosci. 27, 1973–1980 (2007).
Farina, C., Weber, M. S., MeinL, E., Wekerle, H. & Hohlfeld, R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 4, 567–575 (2005).
Bakalash, S. et al. T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure. J. Mol. Med. 83, 904–916 (2005).
Gordon, P. H. et al. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology 66, 1117–1119 (2006).
Laurie, C. et al. CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. J. Neuroimmunol. 183, 60–68 (2007).
Arnon, R., Sela, M. & Teitelbaum, D. New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. J. Neurol. 243, S8–13 (1996).
Liu, J. et al. T cell independent mechanism for copolymer-1-induced neuroprotection. Eur. J. Immunol. 37, 3143–3154 (2007).
Ziv, Y. et al. A novel immune-based therapy for stroke induces neuroprotection and supports neurogenesis. Stroke 38, 774–782 (2007).
Frenkel, D., Maron, R., Burt, D. S. & Weiner, H. L. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest 115, 2423–2433 (2005).
Frenkel, D. et al. A nasal proteosome adjuvant activates microglia and prevents amyloid deposition. Ann. Neurol. 21 March 2008 [epub ahead of print].
Jyothi, M. D., Flavell, R. A. & Geiger, T. L. Targeting autoantigen-specific T cells and suppression of autoimmune encephalomyelitis with receptor-modified T lymphocytes. Nature Biotechnol. 20, 1215–1220 (2002).
Tuohy, V. K. & Mathisen, P. M. T-cell design: optimizing the therapeutic potential of autoreactive T cells by genetic modification. Res. Immunol. 149, 834–842 (1998).
Priller, J. et al. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nature Med. 7, 1356–1361 (2001).
Priller, J. et al. Early and rapid engraftment of bone marrow-derived microglia in scrapie. J. Neurosci. 26, 11753–11762 (2006).
Simard, A. R. & Rivest, S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J. 18, 998–1000 (2004).
Biffi, A. et al. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J. Clin. Inves. 113, 1118–1129 (2004).
Kennedy, K. J., Smith, W. S., Miller, S. D. & Karpus, W. J. Induction of antigen-specific tolerance for the treatment of ongoing, relapsing, autoimmune encephalomyelitis. J. Immunol. 159, 1044 (1997).
Massengale, M., Wagers, A. J., Vogel, H. & Weissman, I. L. Hematopoietic cells maintain hematopoietic fates upon entering the brain. J. Exp. Med. 201, 1579–1589 (2005).
Ajami, B., Bennett, J. L., Krieger, C., Tetzlaff, W. & Rossi, F. M. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nature Neurosci. 10, 1538–1543 (2007).
Mildner, A. et al. Microglia in the adult brain arise from Ly-6C(hi)CCR2(+) monocytes only under defined host conditions. Nature Neurosci. 10, 1544–1553 (2007).
Djukic, M. et al. Circulating monocytes engraft in the brain, differentiate into microglia and contribute to the pathology following meningitis in mice. Brain 129, 2394–2403 (2006).
Takahashi, K., Prinz, M., Stagi, M., Chechneva, O. & Neumann, H. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS. Med. 4, e124 (2007).
Aarum, J., Sandberg, K., Haeberlein, S. L. & Persson, M. A. Migration and differentiation of neural precursor cells can be directed by microglia. Proc. Natl Acad. Sci. USA 100, 15983–15988 (2003).
Muller, F. J., Snyder, E. Y. & Loring, J. F. Gene therapy: can neural stem cells deliver? Nature Rev. Neurosci. 7, 75–84 (2006).
Leavitt, B. R., Hernit-Grant, C. S. & Macklis, J. D. Mature astrocytes transform into transitional radial glia within adult mouse neocortex that supports directed migration of transplanted immature neurons. Exp. Neurol. 157, 43–57 (1999).
Mescher, A. L. & Neff, A. W. Regenerative capacity and the developing immune system. Adv. Biochem. Eng Biotechnol. 93, 39–66 (2005).
Godwin, J. W. & Brockes, J. P. Regeneration, tissue injury and the immune response. J. Anat. 209, 423–432 (2006).
Gordon, S. Alternative activation of macrophages. Nature Rev. Immunol. 3, 23–35 (2003).
Barker, R. N. et al. Antigen presentation by macrophages is enhanced by the uptake of necrotic, but not apoptotic, cells. Clin. Exp. Immunol. 127, 220–225 (2002).
Perez-Capote, K., Serratosa, J. & Sola, C. Excitotoxic and apoptotic neuronal death induce different patterns of glial activation in vitro. J. Neurochem. 94, 226–237 (2005).
Stein, M., Keshav, S., Harris, N. & Gordon, S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation. J. Exp. Med. 176, 287–292 (1992).
Mantovani, A. et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677–686 (2004).
Gratchev, A. et al. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein βIG-H3. Scand. J. Immunol. 53, 386–392 (2001).
Arnold, L. et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J. Exp. Med. 204, 1057–1069 (2007).
Kipnis, J. et al. Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity. J. Neuroimmunol. 130, 78–85 (2002).
Yoles, E. et al. Protective autoimmunity is a physiological response to CNS trauma. J Neurosci. 21, 3740–3748 (2001).
Kipnis, J. et al. Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc. Natl Acad. Sci. USA 99, 15620–15625 (2002).
Kipnis, J., Avidan, H., Caspi, R. R. & Schwartz, M. Dual effect of CD4+CD25+ regulatory T cells in neurodegeneration: a dialogue with microglia. Proc. Natl Acad. Sci. USA 101, S14663–S14669 (2004).
Hauben, E. et al. Vaccination with dendritic cells pulsed with peptides of myelin basic protein promotes functional recovery from spinal cord injury. J. Neurosci. 23, 8808–8819 (2003).
Hauben, E. et al. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J. Clin. Invest 108, 591–599 (2001).
Stinissen, P., Raus, J. & Zhang, J. Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit. Rev. Immunol. 17, 33–75 (1997).
McFarland, H. F. & Martin, R. Multiple sclerosis: a complicated picture of autoimmunity. Nature Immunol. 8, 913–919 (2007).
Wolf, S. A. et al. Neuroprotection by T-cells depends on their subtype and activation state. J. Neuroimmunol. 133, 72–80 (2002).
Hendrix, S. & Nitsch, R. The role of T helper cells in neuroprotection and regeneration. J. Neuroimmunol. 184, 100–112 (2007).
Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E. & Mosley, R. L. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J. Leukoc. Biol. 82, 1083–1094 (2007).
Jones, T. B. et al. Passive or active immunization with myelin basic protein impairs neurological function and exacerbates neuropathology after spinal cord injury in rats. J. Neurosci. 24, 3752–3761 (2004).
Haenggeli, C. et al. Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS. Neurobiol. Dis. 26, 146–152 (2007).
Benveniste, H., Einstein, G., Kim, K. R., Hulette, C. & Johnson, G. A. Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc. Natl Acad. Sci. USA 96, 14079–14084 (1999).
Hand, P. J. et al. Magnetic resonance brain imaging in patients with acute stroke: feasibility and patient related difficulties. J. Neurol. Neurosurg. Psychiatry 76, 1525–1527 (2005).
Morgan, D., Gordon, M. N., Tan, J., Wilcock, D. & Rojiani, A. M. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J. Neuropathol. Exp. Neurol. 64, 743–753 (2005).
Morgan, D. et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982–985 (2000).
Furlan, R. et al. Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain 126, 285–291 (2003).
Yamasaki, Y. et al. New therapeutic possibility of blocking cytokine-induced neutrophil chemoattractant on transient ischemic brain damage in rats. Brain Res. 759, 103–111 (1997).
Bowes, M. P., Rothlein, R., Fagan, S. C. & Zivin, J. A. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 45, 815–819 (1995).
Zhang, X., Hupperts, R. & De Baets, M. Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis. Immunol. Res. 28, 61–78 (2003).
Hurn, P. D. et al. T- and B-cell-deficient mice with experimental stroke have reduced lesion size and inflammation. J. Cereb. Blood Flow Metab 27, 1798–1805 (2007).
Martin-Villalba, A. et al. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death. Differ. 8, 679–686 (2001).
Lovering, F. & Zhang, Y. Therapeutic potential of TACE inhibitors in stroke. CNS & Neurol. Disord. 4, 161–168 (2005).
Lees, K. R., Diener, H. C., Asplund, K. & Krams, M. UK-279276, a neutrophil inhibitory glycoprotein, in acute stroke: tolerability and pharmacokinetics. Stroke 34, 1704–1709 (2003).
Krams, M. et al. Acute stroke therapy by inhibition of neutrophils (ASTIN): an adaptive dose-response study of UK-279276 in acute ischemic stroke. Stroke 34, 2543–2548 (2003).
Enlimomab acute stroke trial investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the enlimomab acute stroke trial. Neurology 57, 1428–1434 (2001).
Emsley, H. C. et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry 76, 1366–1372 (2005).
Morris, D. C. et al. Treatment of acute stroke with recombinant tissue plasminogen activator and abciximab. Acad. Emerg. Med. 10, 1396–1399 (2003).
Topol, E. J. et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 108, 399–406 (2003).
Abciximab emergent stroke treatment trial (AbESTT) investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 36, 880–890 (2005).
Abciximab in ischemic stroke investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. The abciximab in ischemic stroke investigators. Stroke 31, 601–609 (2000).
Bartholdi, D. & Schwab, M. E. Methylprednisolone inhibits early inflammatory processes but not ischemic cell death after experimental spinal cord lesion in the rat. Brain Res. 672, 177–186 (1995).
Xu, J. et al. Methylprednisolone inhibition of TNF-α expression and NF-kB activation after spinal cord injury in rats. Brain Res. Mol. Brain Res. 59, 135–142 (1998).
Bracken, M. B. et al. Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study. J. Neurosurg. 63, 704–713 (1985).
Bracken, M. B. et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N. Engl. J. Med. 322, 1405–1411 (1990).
Bracken, M. B. et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data: Results of the second National Acute Spinal Cord Injury Study. J. Neurosurg. 76, 23–31 (1992).
Bracken, M. B. et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 277, 1597–1604 (1997).
Sayer, F. T., Kronvall, E. & Nilsson, O. G. Methylprednisolone treatment in acute spinal cord injury: the myth challenged through a structured analysis of published literature. Spine J. 6, 335–343 (2006).
Farooque, M., Isaksson, J. & Olsson, Y. Improved recovery after spinal cord trauma in ICAM-1 and P-selectin knockout mice. Neuroreport 10, 131–134 (1999).
Farooque, M., Isaksson, J. & Olsson, Y. White matter preservation after spinal cord injury in ICAM-1/P-selectin-deficient mice. Acta Neuropathol. (Berl) 102, 132–140 (2001).
Taoka, Y. et al. Role of neutrophils in spinal cord injury in the rat. Neuroscience 79, 1177–1182 (1997).
Taoka, Y., Okajima, K., Murakami, K., Johno, M. & Naruo, M. Role of neutrophil elastase in compression-induced spinal cord injury in rats. Brain Res. 799, 264–269 (1998).
Bye, N. et al. Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. Exp. Neurol. 204, 220–233 (2007).
NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66, 664–671 (2006).
Gordon, P. H. et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 62, 1845–1847 (2004).
Jones, N. C. et al. Antagonism of the interleukin-1 receptor following traumatic brain injury in the mouse reduces the number of nitric oxide synthase-2-positive cells and improves anatomical and functional outcomes. Eur. J. Neurosci. 22, 72–78 (2005).
Shohami, E., Bass, R., Wallach, D., Yamin, A. & Gallily, R. Inhibition of tumor necrosis factor α (TNFα) activity in rat brain is associated with cerebroprotection after closed head injury. J. Cereb. Blood Flow Metab 16, 378–384 (1996).
Stirling, D. P. et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J. Neurosci. 24, 2182–2190 (2004).
Festoff, B. W. et al. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J. Neurochem. 97, 1314–1326 (2006).
Nesic, O. et al. IL-1 receptor antagonist prevents apoptosis and caspase-3 activation after spinal cord injury. J. Neurotrauma 18, 947–956 (2001).
Yune, T. Y. et al. Increased production of tumor necrosis factor-α induces apoptosis after traumatic spinal cord injury in rats. J. Neurotrauma 20, 207–219 (2003).
Lee, Y. B. et al. Role of tumor necrosis factor-α in neuronal and glial apoptosis after spinal cord injury. Exp. Neurol. 166, 190–195 (2000).
Tuna, M. et al. Effect of anti-rat interleukin-6 antibody after spinal cord injury in the rat: inducible nitric oxide synthase expression, sodium- and potassium-activated, magnesium-dependent adenosine-5'-triphosphatase and superoxide dismutase activation, and ultrastructural changes. J. Neurosurg. 95, 64–73 (2001).
Bomstein, Y. et al. Features of skin-coincubated macrophages that promote recovery from spinal cord injury. J. Neuroimmunol. 142, 10–16 (2003).
Hauben, E. et al. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J. Neurosci. 20, 6421–6430 (2000).
Jones, T. B. et al. Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: implications for autoimmune vaccine therapy. J. Neurosci. 22, 2690–2700 (2002).
Fox, R. J. & Ransohoff, R. M. New directions in MS therapeutics: vehicles of hope. Trends Immunol. 25, 632–636 (2004).
Mauch, E., Kornhuber, H. H., Krapf, H., Fetzer, U. & Laufen, H. Treatment of multiple sclerosis with mitoxantrone. Eur. Arch. Psychiatry Clin. Neurosci. 242, 96–102 (1992).
Millefiorini, E. et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J. Neurol. 244, 153–159 (1997).
Scott, L. J. & Figgitt, D. P. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 18, 379–396 (2004).
Kerfoot, S. M. et al. Reevaluation of P-selectin and α 4 integrin as targets for the treatment of experimental autoimmune encephalomyelitis. J. Immunol. 176, 6225–6234 (2006).
Tsunoda, I. et al. Modulation of experimental autoimmune encephalomyelitis by VLA-2 blockade. Brain Pathol. 17, 45–55 (2007).
Yu, M., Nishiyama, A., Trapp, B. D. & Tuohy, V. K. Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J. Neuroimmunol. 64, 91–100 (1996).
Polman, C. H. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899–910 (2006).
Miller, D. H. et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15–23 (2003).
O'Connor, P. W. et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 62, 2038–2043 (2004).
Paty, D. W. & Li, D. K. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43, 662–667 (1993).
The IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. D. Neurology 43, 655–661 (1993).
Clerico, M., Contessa, G. & Durelli, L. Interferon-β1a for the treatment of multiple sclerosis. Expert. Opin. Biol. Ther. 7, 535–542 (2007).
Zhang, J., Medaer, R., Stinissen, P., Hafler, D. & Raus, J. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 261, 1451–1454 (1993).
Zhang, J. T cell vaccination as an immunotherapy for autoimmune diseases. Cell Mol. Immunol. 1, 321–327 (2004).
Perumal, J. et al. Glatiramer acetate therapy for multiple sclerosis: a review. Expert. Opin. Drug Metab Toxicol. 2, 1019–1029 (2006).
Kleinschmidt-DeMasters, B. K. & Tyler, K. L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N. Engl. J. Med. 353, 369–374 (2005).
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W. & Pelletier, D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353, 375–381 (2005).
- Adaptive immunity
The response of T and B cells to antigens as a result of infection, injury or intentional immunization. It enables discrimination between self and non-self antigens and the ability to respond more rapidly and efficiently to antigens upon subsequent re-exposure.
A substance, usually an oil, aluminium salt or virosome that amplifies the immune response to an antigen that is injected as part of a vaccine.
Glycoproteins produced by B lymphocytes that are a critical component of adaptive immunity.
An antibody generating molecule that elicits adaptive immunity. It is typically a protein that is processed and presented as part of a complex with MHC molecules to T lymphocytes.
- B lymphocyte
Adaptive immune cell that acts as an antigen presenting cell and produces antibodies against protein and glycoprotein antigens.
- Bystander suppression
The generation of antigen-specific regulatory T cells by oral or nasal administration of low doses of antigen. After these regulatory T cells encounter the autoantigen in the target organ, they release cytokines (for example, IL-10 and TGF-β) that suppress deleterious immune functions.
A family of small (8–10 kD) chemotactic cytokines that promote directed migration in responsive cells.
- Complement proteins
A family of serum proteins that promote opsonization, chemotaxis and cell lysis. They are part of the innate immune system and can be produced in the CNS by glia and neurons.
Originally defined as immune system proteins that modified biological responses, these proteins are now known to be released by most cells and are important in regulating intercellular communication, cell function and cell survival.
Development of excess fibrous connective tissue, usually as a result of injury or infection. It promotes scar formation during wound healing.
- Immune response
Activation of the innate and/or adaptive immune system in response to a disruption of tissue (or systemic) homeostasis.
The complex biological response of vascularized tissues to injury or infection. Derived from the Latin, inflammare (to set on fire), it was historically defined by the clinical signs of pain, redness, heat, swelling and loss of function.
- Innate immunity
A phylogenetically ancient mechanism of defence against pathogens that is comprised of physical and chemical barriers and inducible cells (including monocytes, neutrophils and dendritic cells) or proteins. Unlike the adaptive immune system, it does not require exposure to antigen to become active.
White blood cell derived from multipotent haematopoetic stem cells in the bone marrow. Leukocytes are of myeloid or lymphoid lineage and are found in the blood and lymphatic system.
- Major histocompatability complex (MHC) molecule
Membrane glycoprotein that is essential for recognition of self and non-self antigens by adaptive immune cells.
Circulating precursor of tissue macrophages, an innate immune cell.
- T lymphocyte
A leukocyte involved in triggering, amplifying and regulating immune responses against specific antigens presented by B cells, macrophages (microglia in CNS) or dendritic cells.
- Toll-like receptors
(TLRs). Non-catalytic receptors that recognize structurally conserved molecules found on microbes and non-pathogenic molecules found at sites of tissue injury. TLRs are involved in the activation of innate immune cells.
About this article
Cite this article
Popovich, P., Longbrake, E. Can the immune system be harnessed to repair the CNS?. Nat Rev Neurosci 9, 481–493 (2008). https://doi.org/10.1038/nrn2398
Chondroitin sulfate proteoglycans prevent immune cell phenotypic conversion and inflammation resolution via TLR4 in rodent models of spinal cord injury
Nature Communications (2022)
Synaptic or Non-synaptic? Different Intercellular Interactions with Retinal Ganglion Cells in Optic Nerve Regeneration
Molecular Neurobiology (2022)
Journal of Neuroinflammation (2020)
Kynurenine pathway modulation reverses the experimental autoimmune encephalomyelitis mouse disease progression
Journal of Neuroinflammation (2020)
Neuroscience Bulletin (2020)